Skip to content

At ACADIA, we are committed to improving the lives of patients with neurological and related central nervous system disorders.

About Us

ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders. More »



News

August 05, 2014
ACADIA Pharmaceuticals Reports Second Quarter 2014 Financial Results

July 29, 2014
ACADIA Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 5, 2014

More News »

Product Candidates

We have a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis.   More »


 

Company Information

Investor's Kit Learn More: Pimavanserin Phase III Program for Parkinson's Disease Psychosis »
Investor Webcasts Investor Webcasts »
PDF Corporate Presentation »